Early experience of nintedanib in COVID-19 ARDS-related pulmonary fibrosis: a case series.
Adv Respir Med
; 89(6): 589-596, 2021.
Article
in En
| MEDLINE
| ID: mdl-34966994
ABSTRACT
The current COVID-19 pandemic has spread like wildfire worldwide and has affected millions of people. The novel corona virus mainly affects the lungs leading to life threatening disease like acute respiratory distress syndrome (ARDS). The aftermath of the disease in form of pulmonary fibrosis is upcoming cause of further increase in morbidity and mortality. Nintedanib is an oral antifibrotics with proven role in idiopathic pulmonary fibrosis, however its use in COVID-19 related pulmonary fibrosis has not been studied. We report our early experience of use of nintedanib in COVID-19 related pulmonary fibrosis.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Respiratory Distress Syndrome
/
Respiratory System Agents
/
Idiopathic Pulmonary Fibrosis
/
COVID-19 Drug Treatment
/
Indoles
Type of study:
Etiology_studies
Limits:
Humans
Language:
En
Journal:
Adv Respir Med
Year:
2021
Document type:
Article
Affiliation country:
India